<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Male And Female Genital Tract - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
  
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
  
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}


    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Cerebellum / qBank / Pathology
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">45</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "id": 16859,
    "choices": [
      {
        "id": 67396,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Orchitis </span></span></span></p>"
      },
      {
        "id": 67397,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sertoli cell only tumor </span></span></span></p>"
      },
      {
        "id": 67398,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Testicular atrophy </span></span></span></p>"
      },
      {
        "id": 67399,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-seminomatous germ cell tumor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old male was investigated for infertility. Semen analysis revealed azoospermia and biopsy was taken which is shown in the image. What is the likely diagnosis in the patient?</span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/28/untitled-546.jpg\" style=\"height:189px; width:300px\" /></span></span></p>",
    "unique_key": "Q2398901",
    "question_audio": null,
    "question_video": null,
    "map_id": 32497,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Sertoli cell only tumor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Testicular atrophy </strong>usually <strong>reveals gross atrophy</strong>. Also the <strong>Leydig cells </strong>would have <strong>absent </strong>and there should have been some <strong>expected hormonal disturbances. </strong></span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">So, the preferred answer is Sertoli only syndrome. Also know that in this condition, Sertoli cells are said to have a <strong>wind-swept appearance</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sertoli cell&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">only <strong>syndrome </strong>is consistent with the <strong>absence of germ cells </strong>and <strong>presence of Sertoli cells </strong>in the <strong>seminiferous tubules</strong>, which aligns with the patient&#39;s clinical presentation of infertility and the histological findings.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation;</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Orchitis</strong> usually presents with signs of inflammation, not solely with the absence of germ cells as in the biopsy image.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Testicular atrophy</strong> involves shrinkage and decreased cellular density in the seminiferous tubules, ofte accompanied by fibrosis, which is not demonstrated in the biopsy provided.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Non-seminomatous germ cell tumors</strong> typically display malignant cells with various histologic patterns, which are not evident in the biopsy image.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sertoli cell only syndrome, also known as germ cell aplasia, is diagnosed when testicular biopsy reveals seminiferous tubules with only Sertoli cells and an absence of germ cells, correlating with clinical findings of azoospermia and infertility in a male patient.</span></span></span></p>",
    "correct_choice_id": 67397,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 16863,
    "choices": [
      {
        "id": 67412,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pineal gland</span></span></span></p>"
      },
      {
        "id": 67413,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mediastinum</span></span></span></p>"
      },
      {
        "id": 67414,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retroperitoneum</span></span></span></p>"
      },
      {
        "id": 67415,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sacrococcygeal region</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The commonest site for extragonadal germ cell tumour is:</span></span></p>",
    "unique_key": "Q4178847",
    "question_audio": null,
    "question_video": null,
    "map_id": 32498,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Mediastinum </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Extragonadal germ cell tumors </strong>(EGCTs) are <strong>neoplasms </strong>that <strong>arise from primordial germ cells </strong>outside the gonads. The <strong>most common site </strong>for <strong>EGCTs </strong>is the <strong>mediastinum</strong>, particularly the <strong>anterior mediastinum</strong>. These tumors can also occur in other locations, such as the <strong>pineal gland</strong>, <strong>retroperitoneum</strong>, and <strong>sacrococcygeal region</strong>, but the mediastinum is the most frequently affected site.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">EGCTs&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">most commonly occur in the <strong>mediastinum</strong>, particularly the anterior mediastinum.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Pineal gland.</strong> While EGCTs can occur in the pineal gland, it is <strong>not the most common site </strong>for these tumors.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Retroperitoneum</strong>. EGCTs can also <strong>arise in the retroperitoneum </strong>but <strong>less frequently </strong>than in the mediastinum.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Sacrococcygeal region</strong>. Although <strong>EGCTs </strong>can be <strong>found in the sacrococcygeal region</strong>, it is a less common site compared to the mediastinum.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>mediastinum</strong>, especially the <strong>anterior mediastinum</strong>, is the most common site for <strong>extragonadal germ cell tumors</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 480</span></strong></span></span></p>",
    "correct_choice_id": 67413,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16864,
    "choices": [
      {
        "id": 67416,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">AFP </span></span></span></p>"
      },
      {
        "id": 67417,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">LDH</span></span></span></p>"
      },
      {
        "id": 67418,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">HCG</span></span></span></p>"
      },
      {
        "id": 67419,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">CEA</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which one of the following is not used as a tumor marker in testicular tumors?</span></span></p>",
    "unique_key": "Q7899851",
    "question_audio": null,
    "question_video": null,
    "map_id": 32494,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) CEA </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>CEA </strong>(Carcinoembryonic Antigen) is <strong>not </strong>typically <strong>used as a tumor marker </strong>in <strong>testicular tumors</strong>. It is <strong>increased in </strong></span><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">cancers of the pancreas and colon</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CEA&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(Carcinoembryonic Antigen) is <strong>not </strong>typically <strong>used as a marker for testicular cancer</strong>. It is more commonly associated with <strong>gastrointestinal cancers</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>AFP</strong> (Alpha-fetoprotein) is a <strong>tumor marker </strong>used in the <strong>diagnosis and management </strong>of <strong>non-seminomatous germ cell tumors </strong>of the <strong>testis</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>LDH</strong> (Lactate Dehydrogenase) is a <strong>less specific marker </strong>but can be <strong>elevated in testicular cancers </strong>and is used to gauge prognosis and response to treatment.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>HCG</strong> (Human Chorionic Gonadotropin) is another <strong>marker </strong>important for certain <strong>types of testicular cancers</strong>, such as <strong>choriocarcinomas</strong>, and can also be <strong>elevated </strong>in other <strong>non-seminomatous germ cell tumors</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>tumor markers </strong>commonly used for <strong>testicular cancers </strong>include <strong>AFP, LDH</strong>, and <strong>HCG</strong>. <strong>CEA </strong>is <strong>not </strong>used as a <strong>marker for testicular tumors </strong>and is more relevant in other cancers like those of the gastrointestinal tract. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 981</span></strong></span></span></p>",
    "correct_choice_id": 67419,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16865,
    "choices": [
      {
        "id": 67420,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">PLAP</span></p>"
      },
      {
        "id": 67421,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">C-KIT</span></p>"
      },
      {
        "id": 67422,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">OCT-4</span></p>"
      },
      {
        "id": 67423,
        "text": "<p><span style=\"font-size:12pt;\">CDK-4</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">All of the following molecules are associated with seminoma except:</span></p>",
    "unique_key": "Q6043258",
    "question_audio": null,
    "question_video": null,
    "map_id": 32495,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. D) CDK-4</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Seminomas </strong>are a type of <strong>germ cell tumor of the testes</strong>. The <strong>molecules </strong>associated with <strong>seminoma </strong>include <strong>PLAP </strong>(Placental Alkaline Phosphatase), <strong>C-KIT </strong>(stem cell factor receptor), and <strong>OCT-4 </strong>(Octamer-binding transcription factor 4).</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>CDK-4&nbsp;</strong>(Cyclin-Dependent Kinase 4) is involved in <strong>cell cycle regulation </strong>and is <strong>not </strong>specifically <strong>associated with seminomas. </strong>While <strong>alterations in CDK-4 can be implicated </strong>in various <strong>cancers</strong>, it is not a characteristic marker of seminomatous tumors.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;<strong>PLAP</strong> (Placental Alkaline Phosphatase) is a <strong>tumor marker expressed in seminomas </strong>and can be <strong>used in the diagnosis </strong>and <strong>follow-up of patients </strong>with this type of tumor.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B. C-KIT</strong> is a <strong>proto-oncogene </strong>that <strong>encodes for a tyrosine kinase receptor</strong>; mutations in C-KIT are found in a subset of seminomas, making it relevant to their pathogenesis.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. OCT-4</strong> (Octamer-binding transcription factor 4) is a <strong>transcription factor </strong>involved in <strong>maintaining the pluripotency </strong>of <strong>embryonic stem cells</strong>. It is highly expressed in seminomas and is considered a reliable diagnostic marker.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">When <strong>assessing seminomas</strong>, key genes to consider include <strong>PLAP, C-KIT, </strong>and <strong>OCT-4</strong>, which are commonly <strong>expressed in these tumors</strong>. <strong>CDK-4 </strong>is <strong>not </strong>specifically <strong>linked to seminomas </strong>and is more generally <strong>involved in the cell cycle regulation </strong>of <strong>many cell types</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Ref</u>: Robbins 10th/ 978</strong></span></p>",
    "correct_choice_id": 67423,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16870,
    "choices": [
      {
        "id": 67440,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Call Exner body</span></span></span></p>"
      },
      {
        "id": 67441,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Psammoma body</span></span></span></p>"
      },
      {
        "id": 67442,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schiller-Duval body</span></span></span></p>"
      },
      {
        "id": 67443,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homer wright body</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endodermal sinus tumor is characterized by:</span></span></span></p>",
    "unique_key": "Q8208503",
    "question_audio": null,
    "question_video": null,
    "map_id": 32496,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Schiller-Duval body </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Endodermal sinus tumor </strong>(also known as yolk sac tumor) is a <strong>malignant germ cell tumor </strong>that can occur in the <strong>ovaries and testes</strong>. It is characterized <strong>histologically </strong>by the <strong>presence of Schiller-Duval bodies</strong>. <strong>Schiller-Duval bodies </strong>are <strong>glomerulus-like structures </strong>formed by <strong>tumor cells </strong>arranged <strong>around a central blood vessel. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Call Exner body:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen in <strong>granulosa cell tumors </strong>of the <strong>ovary</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Psammoma body:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen in <strong>various tumors</strong>, including <strong>papillary thyroid carcinoma </strong>and <strong>serous ovarian tumors</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Homer Wright body:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen in <strong>neuroblastoma </strong>and <strong>medulloblastoma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>presence of Schiller-Duval bodies </strong>is a distinctive <strong>histological feature </strong>of <strong>endodermal sinus tumors </strong>(yolk sac tumors), which are <strong>aggressive germ cell neoplasms </strong>often found in the <strong>gonads</strong>. Recognition of these bodies, which <strong>resemble a glomerulus </strong>with a <strong>central blood vessel </strong>surrounded by <strong>germ cells</strong>, aids in <strong>differentiating endodermal sinus tumors </strong>from <strong>other germ cell tumors</strong>. They are a pathognomonic finding, supporting the diagnosis when identified microscopically.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 974</span></strong></span></span></p>",
    "correct_choice_id": 67442,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16862,
    "choices": [
      {
        "id": 67408,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Central zone</span></span></span></p>"
      },
      {
        "id": 67409,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Peripheral zone</span></span></span></p>"
      },
      {
        "id": 67410,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Periurethral transition zone</span></span></span></p>"
      },
      {
        "id": 67411,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Any of the above</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Benign hyperplasia of prostate first develops in:</span></span></p>",
    "unique_key": "Q5360404",
    "question_audio": null,
    "question_video": null,
    "map_id": 32517,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Periurethral transition zone </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Benign prostatic hyperplasia </strong>(BPH) is a common condition characterized by the <strong>non-cancerous growth </strong>of the <strong>prostate gland</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>BPH </strong>usually <strong>first develops in the periurethral transition zone</strong>, which surrounds the <strong>urethra </strong>as it exits the bladder.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As the <strong>prostate enlarges</strong>, it can <strong>compress the urethra </strong>and lead to symptoms such as <strong>urinary frequency</strong>, <strong>urgency</strong>, and <strong>difficulty in initiating urination</strong>.</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>central </strong>and <strong>peripheral zones </strong>of the <strong>prostate </strong>are <strong>less commonly involved </strong>in the <strong>initial stages of BPH</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">As BPH typically starts in the periurethral transition zone.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Incorrect, as the <strong>central zone </strong>is <strong>not the typical starting point for BPH</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Incorrect, because the <strong>peripheral zone </strong>is primarily <strong>associated with prostate cancer </strong>rather than BPH.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Benign prostatic hyperplasia </strong>commonly <strong>begins in the periurethral transition zone </strong>of the <strong>prostate</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 982</span></strong></span></span></p>",
    "correct_choice_id": 67410,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16856,
    "choices": [
      {
        "id": 67384,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Methanol</span></p>"
      },
      {
        "id": 67385,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Ethanol</span></p>"
      },
      {
        "id": 67386,
        "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\">Formalin</span></p>"
      },
      {
        "id": 67387,
        "text": "<p><span style=\"font-size:12pt;\">Air drying</span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify;\"><span style=\"font-size:12.0pt;\">A 32-year-old woman presents for a routine Pap smear. The cytology report reveals koilocytes, nuclear enlargement, and perinuclear clearing in some of the cells. The fixative used in Pap smear is:</span></p>",
    "unique_key": "Q6537949",
    "question_audio": null,
    "question_video": null,
    "map_id": 32489,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ans. B) Ethanol</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option B:</strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ethanol (95%)</strong> is the <strong>preferred fixative for Pap smears </strong>as it adequately <strong>preserves the cytological features </strong>necessary for the <strong>detection of abnormal cells</strong>, including <strong>precancerous </strong>and <strong>cancerous changes</strong>.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Explanation:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option A. Methanol</strong> is a <strong>fixative </strong>but <strong>not the primary choice for Pap smears </strong>because it can cause shrinkage and hardening of cells, which may interfere with cytological interpretation.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option C. Formalin</strong> is used for <strong>histopathological specimens </strong>and is not suitable for Pap smears, as it can over-fix cells, leading to difficulties in cytological interpretation.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Option D. Air drying</strong> is <strong>not a fixative </strong>and can <strong>result in poor preservation of cellular morphology </strong>on Pap smear slides.</span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong><u>Educational Objective:</u></strong></span></p><p style=\"text-align:justify;\">&nbsp;</p><p style=\"text-align:justify;\"><span style=\"font-size:12pt;\"><strong>Ethanol </strong>is the <strong>primary fixative </strong>used in <strong>Pap smear preparations</strong>, effectively <strong>preserving the morphology of cervical cells </strong>for <strong>cytological evaluation </strong>and the <strong>identification of abnormalities </strong>such as <strong>koilocytes</strong>, which are indicative of HPV infection.</span></p>",
    "correct_choice_id": 67385,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": "",
    "video_explanation_heading": "",
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 16857,
    "choices": [
      {
        "id": 67388,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cytobrush </span></span></span></p>"
      },
      {
        "id": 67389,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ayer spatula</span></span></span></p>"
      },
      {
        "id": 67390,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fixative and retractor </span></span></span></p>"
      },
      {
        "id": 67391,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the above</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following are the instruments used in Pap smear:</span></span></p>",
    "unique_key": "Q5394512",
    "question_audio": null,
    "question_video": null,
    "map_id": 32490,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) All of the above </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Pap smear procedure </strong>involves using various <strong>instruments to collect cells </strong>from the <strong>cervix </strong>for examination. These instruments include:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Cytobrush:</strong> It is a <strong>brush-like instrument </strong>used to <strong>collect cells from the endocervical canal</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><span style=\"font-family:Calibri,sans-serif\"><strong>B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ayer spatula</strong>: It is a <strong>wooden or plastic spatula </strong>used to <strong>sample cells </strong>from the<strong> outer cervix</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option&nbsp;</span></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Fixative and Retractor:</strong> After <strong>collecting the cells</strong>, they are <strong>transferred onto a glass slide</strong>, <strong>fixed</strong>, and then <strong>examined under a microscope</strong>. A retractor may be used to help visualize and access the cervix during the procedure.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the mentioned instruments (cytobrush, Ayer spatula, fixative, and retractor) are used in the Pap smear procedure.</span></span></span></p>",
    "correct_choice_id": 67391,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16858,
    "choices": [
      {
        "id": 67392,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">4, 3, 2, 1</span></span></span></p>"
      },
      {
        "id": 67393,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">4, 3, 1, 2</span></span></span></p>"
      },
      {
        "id": 67394,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2, 3, 4</span></span></span></p>"
      },
      {
        "id": 67395,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">1, 2, 4, 3</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Arrange the steps of Pap smear in the correct sequence:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retract vagina</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Take smear</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Make smear on the slide</span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fixate the slide</span></span></span></li>\r\n</ol>",
    "unique_key": "Q9778977",
    "question_audio": null,
    "question_video": null,
    "map_id": 32491,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 1, 2, 3, 4</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/23/screenshot-2024-04-23-163037.png\" style=\"height:561px; width:1000px\" /></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The steps of <strong>Pap smear </strong>include <strong>retracting the vagina </strong>to <strong>visualize the cervix</strong>, taking a <strong>smear of cervical cells</strong>, making a <strong>smear on a slide</strong>, and <strong>fixating the slide </strong>with a <strong>suitable fixative </strong>like <strong>ethanol </strong>to <strong>preserve the sample </strong>for <strong>transportation and analysis</strong>. </span></span></span></p>",
    "correct_choice_id": 67394,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16860,
    "choices": [
      {
        "id": 67400,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">6 </span></span></span></p>"
      },
      {
        "id": 67401,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">11</span></span></span></p>"
      },
      {
        "id": 67402,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">18 </span></span></span></p>"
      },
      {
        "id": 67403,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">32</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female presented in the gynecology OPD with the presentation as given in the image. The examination revealed presence of high-risk HPV. Which of the following is the causative agent?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/28/untitled-547.jpg\" style=\"height:253px; width:300px\" /></span></span></p>",
    "unique_key": "Q4169318",
    "question_audio": null,
    "question_video": null,
    "map_id": 32492,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 18 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The question has an image showing <strong>multiple vagino-cervical warts</strong>. If we read the stem of the question, it makes a mention of <strong>high-risk HPV subtype</strong> and so, the answer is <strong>HPV 16</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HPV 18</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>correct answer</strong>. It is one of the <strong>high-risk HPV types </strong>known to be associated with <strong>cervical cancer </strong>and <strong>high-grade dysplasia</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. HPV 6</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is incorrect because it is <strong>associated with low-risk lesions </strong>such as <strong>genital warts </strong>rather than high-risk cervical pathologies.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. HPV 11</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is also incorrect for the <strong>same reason as HPV 6</strong>; it is linked to benign lesions and not high-risk cervical dysplasias or cancers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. HPV 32</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not typically <strong>implicated in high-risk cervical disease</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>HPV 16 </strong>and <strong>18 are involved in the pathogenesis </strong>of <strong>high-grade cervical dysplasias </strong>and <strong>cervical cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1001</span></strong></span></span></p>",
    "correct_choice_id": 67402,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 16861,
    "choices": [
      {
        "id": 67404,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypertrophy</span></span></span></p>"
      },
      {
        "id": 67405,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dysplasia</span></span></span></p>"
      },
      {
        "id": 67406,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metaplasia</span></span></span></p>"
      },
      {
        "id": 67407,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperplasia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 30-year-old woman undergoes Pap smear which shows disorganised growth of the cells with hyperchromatic nuclei. Which phenomenon is occurring here?</span></span></span></p>",
    "unique_key": "Q4968427",
    "question_audio": null,
    "question_video": null,
    "map_id": 32493,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Dysplasia </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dysplasia </strong>refers to <strong>abnormal growth</strong>, <strong>development</strong>, or <strong>maturation of cells within a tissue</strong>. In the context of a <strong>Pap smear</strong>, <strong>dysplasia </strong>typically indicates <strong>abnormal changes in cervical cells </strong>that may progress to cervical cancer if not addressed. <strong><em>Disorganized growth of cells with hyperchromatic nuclei is a characteristic feature of dysplasia.</em></strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypertrophy</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> refers to an <strong>increase in the size of cells </strong>without an increase in the number of cells.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Metaplasia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>reversible change </strong>in which one adult cell type is replaced by another cell type.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hyperplasia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is an <strong>increase in the number of cells </strong>in a <strong>tissue </strong>or organ.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dysplasia </strong>represents an <strong>early sign </strong>of potential <strong>malignant transformation </strong>in <strong>cervical epithelial cells </strong>and is characterized by <strong>disorganized cellular architecture </strong>and <strong>nuclear atypia</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10th/e p719-720</span></strong></span></span></p>",
    "correct_choice_id": 67405,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 16866,
    "choices": [
      {
        "id": 67424,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metaphase is distinct </span></span></span></p>"
      },
      {
        "id": 67425,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Due to contamination with infectious agents</span></span></span></p>"
      },
      {
        "id": 67426,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">High mitotic rate</span></span></span></p>"
      },
      {
        "id": 67427,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Deficient tissue sample</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The cytogenicity of solid tumors is not easily assessed especially in carcinoma cervix because:</span></span></p>",
    "unique_key": "Q5905795",
    "question_audio": null,
    "question_video": null,
    "map_id": 32487,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Due to contamination with infectious agents </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Contamination </strong>with <strong>infectious agents </strong>could <strong>introduce foreign genetic material</strong>, making it <strong>challenging to obtain accurate </strong>and <strong>reliable cytogenetic results</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">While a <strong>high mitotic rate</strong> is a <strong>characteristic of rapidly dividing cancer cells</strong>, it <strong>doesn&#39;t </strong>necessarily <strong>hinder cytogenetic analysis</strong>. In fact, a <strong>high mitotic rate </strong>is often <strong>beneficial for cytogenetic studies </strong>as it provides more cells in the dividing phase for analysis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Deficient tissue sample</strong>: A <strong>deficient tissue sample </strong>may indeed <strong>hinder cytogenetic analysis</strong>. If the <strong>sample is insufficient </strong>or of <strong>low quality</strong>, it may not yield enough viable cells for proper analysis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Deficient tissue sampling </strong>like <strong>sampling from non-representative areas </strong>or the <strong>necrotic areas </strong>will <strong>impair the results </strong>in most of the <strong>solid tumors </strong>but the <strong>commonest problem with cancer of the cervix </strong>is the <strong>high contamination rate</strong>. So, option &lsquo;B&rsquo; is better than option &lsquo;D&rsquo;.</span></span></span></p>",
    "correct_choice_id": 67425,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 16874,
    "choices": [
      {
        "id": 67456,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Caused by HPV</span></span></span></p>"
      },
      {
        "id": 67457,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sexually transmitted</span></span></span></p>"
      },
      {
        "id": 67458,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progresses to malignancy</span></span></span></p>"
      },
      {
        "id": 67459,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Occurs in genitalia</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All are true about condylomata acuminata except which of the following:</span></span></p>",
    "unique_key": "Q4159471",
    "question_audio": null,
    "question_video": null,
    "map_id": 32488,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Progresses to malignancy</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>HPV infection </strong>is associated with certain <strong>cancers</strong>, particularly <strong>cervical cancer</strong>, <strong>condylomata acuminata </strong>themselves are <strong>benign </strong>and <strong>rarely progress to malignancy</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Caused by HPV</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is <strong>true</strong>. Condylomata acuminata, also known as genital warts, are caused by certain types of the human papillomavirus (HPV), particularly HPV types 6 and 11.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Sexually transmitted</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is <strong>true </strong>as well. HPV, which causes condylomata acuminata, is transmitted through sexual contact.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Occurs in genitalia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This statement is <strong>true</strong>. Condylomata acuminata typically appear in the moist mucocutaneous regions of the genitalia and are characterized by their cauliflower-like appearance.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Condylomata acuminata </strong>are <strong>benign lesions </strong>caused by <strong>HPV </strong>and are <strong>sexually transmitted</strong>. They typically <strong>appear in the genitalia </strong>and, while they may persist or recur, they <strong>rarely progress to malignancy</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 970</span></strong></span></span></p>",
    "correct_choice_id": 67458,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 41593,
    "choices": [
      {
        "id": 166060,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dysgerminoma</span></span></span></p>"
      },
      {
        "id": 166061,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teratoma</span></span></span></p>"
      },
      {
        "id": 166062,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Yolk sac tumor</span></span></span></p>"
      },
      {
        "id": 166063,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Granulosa cell tumor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old female presents with abdominal pain and a pelvic mass. Histological examination of the ovarian tumor reveals the presence of Schiller-Duval bodies. Which of the following is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q9849845",
    "question_audio": null,
    "question_video": null,
    "map_id": 32486,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Yolk sac tumor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Schiller-Duval bodies </strong>are a <strong>histological finding </strong>characteristic of <strong>yolk sac tumors</strong>. <strong>Yolk sac tumors </strong>(also known as endodermal sinus tumors) are <strong>malignant ovarian germ cell tumors </strong>that <strong>histologically mimic the yolk sac </strong>of the <strong>developing embryo</strong>. <strong>Schiller-Duval bodies </strong>are <strong>glomerulus-like structures </strong>and are composed of a <strong>central blood vessel </strong>surrounded by <strong>layers of tumor cells</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/04/23/screenshot-2024-04-23-160557.png\" style=\"height:177px; width:300px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>A</strong>. <strong>Dysgerminoma </strong>are type of <strong>ovarian germ cell tumor</strong>, but they are characterized by <strong>monotonous sheets of large</strong>, <strong>undifferentiated cells </strong>resembling <strong>primordial germ cells</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>B</strong>. <strong>Teratoma </strong>are <strong>composed of multiple germ cell layers </strong>and can <strong>contain a variety of tissues </strong>such as <strong>epithelium, hair</strong>, and <strong>cartilage</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>D</strong>. <strong>Granulosa cell tumors&nbsp; </strong>are <strong>sex cord-stromal tumors</strong>, and they are characterized by the <strong>presence of Call-Exner bodies</strong>. These bodies are small, eosinophilic fluid-filled spaces surrounded by granulosa cells.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>presence of Schiller-Duval bodies </strong>in an <strong>ovarian mass biopsy </strong>is <strong>pathognomonic for yolk sac tumors</strong>, also known as <strong>endodermal sinus tumors</strong>, and is the most likely diagnosis in a <strong>young woman </strong>presenting with these histological findings.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1025</span></strong></span></span></p>",
    "correct_choice_id": 166062,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16853,
    "choices": [
      {
        "id": 67372,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teratoma: Epithelium, hair and cartilage</span></span></span></p>"
      },
      {
        "id": 67373,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dysgerminoma: Nonlymphocytic infiltration </span></span></span></p>"
      },
      {
        "id": 67374,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Yolk sac tumor: Schiller Duval body</span></span></span></p>"
      },
      {
        "id": 67375,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Granulosa cell tumor: Call Exner body</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which is not a correct match for the following ovarian tumors and their histological findings?</span></span></p>",
    "unique_key": "Q6195642",
    "question_audio": null,
    "question_video": null,
    "map_id": 32485,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Dysgerminoma: Nonlymphocytic infiltration</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dysgerminoma </strong>is a type of <strong>ovarian germ cell tumor</strong>, and its histological features typically include <strong>lymphocytic infiltration</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dysgerminomas </strong>are <strong>germ cell tumors </strong>that typically include <strong>lymphocytic infiltration</strong>, not &quot;nonlymphocytic infiltration.&quot;</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Correct.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Teratomas </strong>are <strong>mixed germ cell tumors </strong>that can contain <strong>various types of tissue</strong>, such as <strong>hair, skin, </strong>and <strong>teeth, </strong>reflecting their origin from multiple germ layers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Correct.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Yolk sac tumors </strong>are characterized by the <strong>presence of Schiller-Duval bodies</strong>, a distinctive histological feature.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Correct</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Granulosa cell tumors </strong>are often characterized by the <strong>presence of Call-Exner bodies.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Dysgerminomas </strong>typically <strong>exhibit lymphocytic infiltration</strong>, <strong>not nonlymphocytic infiltration</strong>, distinguishing them from the other tumor types listed. This is crucial for pathology recognition and accurate diagnosis in the clinical setting.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1025-6</span></strong></span></span></p>",
    "correct_choice_id": 67373,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 16868,
    "choices": [
      {
        "id": 67432,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vimentin, epithelial membrane antigen, inhibin, CD99</span></span></span></p>"
      },
      {
        "id": 67433,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Desmin, S-100 protein, smooth muscle antigen, cytokeratin</span></span></span></p>"
      },
      {
        "id": 67434,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chromogranin, CD45, CD99, CD20</span></span></span></p>"
      },
      {
        "id": 67435,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">CD3, Chromogranin, CD 45, Synaptophysin</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sections from a solid-cystic unilateral ovarian tumor in a 30-year-old female show a tumor composed of diffuse sheets of small cells with doubtful nuclear grooving and scanty cytoplasm. No Call-Exner bodies are seen.&nbsp; The ideal immunohistochemistry panel would include:</span></span></span></p>",
    "unique_key": "Q4293591",
    "question_audio": null,
    "question_video": null,
    "map_id": 32479,
    "difficulty_level": "difficult",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Vimentin, epithelial membrane antigen, inhibin, CD99 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>specimen </strong>in the given question is most likely to be of <strong>granulosa cell tumor of ovary</strong>: The features pointing toward this diagnosis are: </span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unilateral tumor </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Solid and cystic areas</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Small cells arranged in sheets </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nuclear grooving </span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Scant cytoplasm </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The only <strong>point against this diagnosis </strong>is <strong>absence of Call-Exner bodies</strong>, but note that these structures if found are diagnostic of Granulosa cell tumors but these are not prerequisite for diagnosis. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following <strong>panel helps in confirming the sex cord-stromal nature </strong>of the <strong>tumor</strong>, <strong>narrowing down to granulosa cell tumors</strong>, and ruling out other possibilities.</span></span></span>\r\n\t<ul>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vimentin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>marker for mesenchymal tissue</strong>, including ovarian stromal cells.</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epithelial membrane antigen (EMA):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Often <strong>positive in granulosa cell tumors</strong>.</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibin:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> A <strong>specific marker for sex cord-stromal tumors</strong>, particularly granulosa cell tumors.</span></span></span></li>\r\n\t\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CD99:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Can be <strong>expressed in sex cord-stromal tumors </strong>and is useful for confirming the diagnosis.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">includes Vimentin</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, which is a mesenchymal marker and may be expressed in granulosa cell tumors, which are of stromal origin. Epithelial membrane antigen (EMA) is not typically expressed in granulosa cell tumors, but when it is, it can support the diagnosis. Inhibin is a specific marker for sex cord-stromal tumors and is particularly strong in granulosa cell tumors. CD99 is less specific but can support the diagnosis when other markers are also positive.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Encompasses markers </strong>like <strong>Desmin and Smooth Muscle Antigen </strong>(SMA) for <strong>smooth muscle tumors</strong>, <strong>S-100 </strong>for <strong>neural tumors</strong>, and <strong>Cytokeratin for epithelial tumors</strong>. This panel isn&rsquo;t as specific for granulosa cell tumors as Option A.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Has <strong>markers like Chromogranin </strong>and <strong>CD45</strong>, which are <strong>used for neuroendocrine </strong>and <strong>hematolymphoid tumors</strong>, respectively. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Includes <strong>CD3 and CD45</strong>, <strong>markers for T-lymphocytes </strong>and <strong>leukocytes </strong>respectively, along with <strong>Chromogranin </strong>and <strong>Synaptophysin</strong>, which are neuroendocrine markers. This panel is not suitable for a granulosa cell tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In <strong>diagnosing granulosa cell tumors</strong>, an <strong>IHC panel including Vimentin, EMA</strong>, <strong>Inhibin</strong>, and <strong>CD99 </strong>can be <strong>valuable</strong>. <strong>Vimentin </strong>and <strong>Inhibin </strong>are particularly important in this setting, with <strong>Inhibin being a specific marker for sex cord-stromal tumors </strong>like <strong>granulosa cell tumors</strong>. The <strong>absence of Call-Exner bodies </strong>does <strong>not exclude the diagnosis of granulosa cell tumors</strong>, as these are not present in all cases. This panel can help confirm the diagnosis and differentiate it from other neoplasms.</span></span></span></p>",
    "correct_choice_id": 67432,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16870,
    "choices": [
      {
        "id": 67440,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Call Exner body</span></span></span></p>"
      },
      {
        "id": 67441,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Psammoma body</span></span></span></p>"
      },
      {
        "id": 67442,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Schiller-Duval body</span></span></span></p>"
      },
      {
        "id": 67443,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Homer wright body</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endodermal sinus tumor is characterized by:</span></span></span></p>",
    "unique_key": "Q8208503",
    "question_audio": null,
    "question_video": null,
    "map_id": 32480,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Schiller-Duval body </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Endodermal sinus tumor </strong>(also known as yolk sac tumor) is a <strong>malignant germ cell tumor </strong>that can occur in the <strong>ovaries and testes</strong>. It is characterized <strong>histologically </strong>by the <strong>presence of Schiller-Duval bodies</strong>. <strong>Schiller-Duval bodies </strong>are <strong>glomerulus-like structures </strong>formed by <strong>tumor cells </strong>arranged <strong>around a central blood vessel. </strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Call Exner body:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen in <strong>granulosa cell tumors </strong>of the <strong>ovary</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Psammoma body:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen in <strong>various tumors</strong>, including <strong>papillary thyroid carcinoma </strong>and <strong>serous ovarian tumors</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Homer Wright body:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Seen in <strong>neuroblastoma </strong>and <strong>medulloblastoma.</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>presence of Schiller-Duval bodies </strong>is a distinctive <strong>histological feature </strong>of <strong>endodermal sinus tumors </strong>(yolk sac tumors), which are <strong>aggressive germ cell neoplasms </strong>often found in the <strong>gonads</strong>. Recognition of these bodies, which <strong>resemble a glomerulus </strong>with a <strong>central blood vessel </strong>surrounded by <strong>germ cells</strong>, aids in <strong>differentiating endodermal sinus tumors </strong>from <strong>other germ cell tumors</strong>. They are a pathognomonic finding, supporting the diagnosis when identified microscopically.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 974</span></strong></span></span></p>",
    "correct_choice_id": 67442,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16871,
    "choices": [
      {
        "id": 67444,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thecoma</span></span></span></p>"
      },
      {
        "id": 67445,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Brenner tumour</span></span></span></p>"
      },
      {
        "id": 67446,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serous cystadenoma</span></span></span></p>"
      },
      {
        "id": 67447,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Granulose cell tumor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An adenofibroma of the ovary in which the epithelial component consists of the nests of transitional cells is called:</span></span></p>",
    "unique_key": "Q9544106",
    "question_audio": null,
    "question_video": null,
    "map_id": 32481,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Brenner tumour </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Brenner tumor </strong>is an <strong>ovarian tumor </strong>characterized by the <strong>presence of nests of transitional epithelial cells</strong>. It is a <strong>subtype of ovarian epithelial tumor </strong>and is typically <strong>benign</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Thecoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An <strong>ovarian sex cord-stromal tumor</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Serous cystadenoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> An <strong>ovarian epithelial tumor </strong>characterized by the <strong>presence of serous cysts</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Granulosa cell tumor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Another type of <strong>ovarian sex cord-stromal tumor</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Brenner tumor </strong>is an <strong>uncommon ovarian neoplasm </strong>characterized by <strong>solid and cystic components </strong>with <strong>transitional epithelium </strong>resembling <strong>bladder urothelium</strong>. The histopathological features of Brenner tumours often present as nests of transitional cells.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1025</span></strong></span></span></p>",
    "correct_choice_id": 67445,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 16872,
    "choices": [
      {
        "id": 67448,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dysgerminoma </span></span></span></p>"
      },
      {
        "id": 67449,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Krukenberg tumor </span></span></span></p>"
      },
      {
        "id": 67450,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucinous adenocarcinoma of the ovaries</span></span></span></p>"
      },
      {
        "id": 67451,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dermoid cyst</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A lady with abdominal mass was investigated. On surgery, she was found to have bilateral ovarian masses with smooth surface. On microscopy they revealed mucin secreting cells with signet ring shape. What is the most likely diagnosis?</span></span></span></p>",
    "unique_key": "Q2410523",
    "question_audio": null,
    "question_video": null,
    "map_id": 32482,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Krukenberg tumor </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>classic metastatic gastrointestinal carcinoma </strong>involving the <strong>ovaries </strong>is termed <strong>Krukenberg tumor</strong>, characterized by <strong>bilateral metastases </strong>composed of <strong>mucin-producing</strong>, <strong>signet-ring cancer cells</strong>, most often of <strong>gastric origin</strong>.</span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Krukenberg tumors </strong>are <strong>metastatic gastrointestinal cancers</strong>, most commonly from the <strong>stomach</strong>, that <strong>spread to the ovaries</strong>. The key histological feature is the <strong>presence of mucin-secreting signet ring cells</strong>. The cells have a <strong>&quot;signet ring&quot; appearance </strong>because the <strong>mucin pushes the nucleus to the periphery</strong>. These tumors are often <strong>bilateral with a smooth surface</strong>, which fits the description given in the scenario.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Dysgerminoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Dysgerminomas are <strong>germ cell tumors </strong>typically <strong>found in the ovaries</strong>. Histologically, they are characterized by uniform, undifferentiated cells with clear cytoplasm and central nuclei. They do not have the mucin-secreting signet ring cells that are characteristic of Krukenberg tumors.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Mucinous Adenocarcinoma of the Ovaries:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>Primary mucinous adenocarcinomas </strong>of the <strong>ovaries originate within the ovary itself</strong>. They also contain mucin-secreting cells, but unlike Krukenberg tumors, they are not metastatic and typically present as multilocular cystic masses with a sticky gelatinous fluid.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Dermoid Cyst:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Also known as <strong>mature cystic teratomas</strong>, <strong>dermoid cysts </strong>are <strong>benign tumors </strong>that contain <strong>well-differentiated derivations </strong>from at least <strong>two of the three germ layers</strong>: <strong>ectoderm</strong>, <strong>mesoderm</strong>, and <strong>endoderm</strong>. They may contain various tissues such as hair, teeth, and sebaceous material, and are not associated with signet ring cells or mucin production.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>presence of bilateral ovarian masses </strong>with <strong>mucin-secreting signet ring cells </strong>is <strong>pathognomonic for a Krukenberg tumor</strong>, which indicates that the <strong>primary tumor </strong>is most likely in the <strong>gastrointestinal tract</strong>, especially the <strong>stomach</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1030</span></strong></span></span></p>",
    "correct_choice_id": 67449,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "InvestigationBased"
    ]
  },
  {
    "id": 16876,
    "choices": [
      {
        "id": 67464,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroma </span></span></span></p>"
      },
      {
        "id": 67465,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teratoma</span></span></span></p>"
      },
      {
        "id": 67466,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucinous cystadenoma</span></span></span></p>"
      },
      {
        "id": 67467,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serous cystadenoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common primary ovarian tumor amongst the following is:</span></span></p>",
    "unique_key": "Q4113411",
    "question_audio": null,
    "question_video": null,
    "map_id": 32483,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Serous cystadenoma </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Serous cystadenomas </strong>are <strong>ovarian tumors </strong>that <strong>contain serous fluid</strong>, and while they are the <strong>most common ovarian neoplasms</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Fibroma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Fibromas are <strong>ovarian tumors </strong>composed of <strong>fibrous tissue</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Ovarian teratomas</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, also known as <strong>dermoid cysts</strong>, are the <strong>neoplasms </strong>that can contain elements derived from all three germ layers (ectoderm, mesoderm, and endoderm)</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Mucinous cystadenoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Mucinous cystadenomas are <strong>ovarian tumors</strong> that contain<strong> mucin-secreting epithelial cells</strong>..</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Serous cystadenomas </strong>are the <strong>most common ovarian neoplasms</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1024</span></strong></span></span></p>",
    "correct_choice_id": 67467,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 16882,
    "choices": [
      {
        "id": 67488,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Partial hydatiform mole</span></span></span></p>"
      },
      {
        "id": 67489,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial hyperplasia</span></span></span></p>"
      },
      {
        "id": 67490,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metastases to uterine serosa</span></span></span></p>"
      },
      {
        "id": 67491,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Condyloma acuminate of cervix</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 62-year-old woman experienced dull pain in lower abdomen for past 6 months and minimal vaginal bleeding on 3 occasions. Her last menstrual period was 12 years ago. Pelvic examination shows a right adnexal mass and the uterus appears normal in size. An abdominal ultrasound shows 8 cm solid mass. A total abdominal hysterectomy was done and mass was diagnosed as granulosa tumour. Which of the following additional lesion is most likely to be found in excised specimen?</span></span></p>",
    "unique_key": "Q8262215",
    "question_audio": null,
    "question_video": null,
    "map_id": 32484,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans B) Endometrial hyperplasia</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most&nbsp;<strong><em>granulosa cell tumours</em></strong> are <strong><em>hormonally active </em></strong>and <strong><em>secrete estrogens</em></strong> that can lead to <strong><em>endometrial hyperplasia</em></strong>. Most of these tumours are benign and do not metastasize. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>A partial hydatidiform mole</strong> is a <strong>gestational trophoblastic disease </strong>characterized by <strong>abnormal fetal development </strong>and <strong>hydropic changes </strong>in the <strong>placenta</strong>. It&#39;s more associated with <strong>abnormalities in fertilization </strong>and <strong>placental development </strong>during <strong>pregnancy</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>While metastases can occur in various cancers</strong>, <strong>granulosa cell tumors </strong>of the <strong>ovary </strong>typically <strong>spread within the pelvic </strong>and <strong>abdominal cavities</strong>. Distant metastases, especially to the uterine serosa, are less common.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Condyloma acuminata</strong>, caused by <strong>human papillomavirus </strong>(HPV), is a <strong>sexually transmitted infection </strong>that manifests as <strong>genital warts</strong>. It is unrelated to granulosa cell tumors of the ovary.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is important to <strong>recognize the endocrine effects of granulosa cell tumors</strong>, which are a <strong>type of sex cord-stromal tumor </strong>of the <strong>ovary</strong>. These <strong>tumors </strong>are known to <strong>secrete estrogen</strong>, which can lead to <strong>proliferative changes </strong>in the <strong>endometrium</strong>, such as <strong>endometrial hyperplasia</strong>. In <strong>postmenopausal women</strong>, <strong>unopposed estrogen </strong>can significantly <strong>increase the risk of developing endometrial hyperplasia</strong>, which can progress to <strong>endometrial carcinoma</strong>. </span></span></span></p>",
    "correct_choice_id": 67489,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 14971,
    "choices": [
      {
        "id": 59844,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hemolysis </span></span></span></span></p>"
      },
      {
        "id": 59845,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated liver enzymes </span></span></span></span></p>"
      },
      {
        "id": 59846,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombocytopenia </span></span></span></span></p>"
      },
      {
        "id": 59847,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retroplacental hemorrhage</span></span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not a part of HELLP syndrome? </span></span></p>",
    "unique_key": "Q2589441",
    "question_audio": null,
    "question_video": null,
    "map_id": 32448,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Retroplacental hemorrhage </span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>subclinical hepatic disease </strong>may be the <strong>primary manifestation of preeclampsia</strong>, as part of a <strong>syndrome of <em>h</em>emolysis</strong>, <strong><em>e</em>levated <em>l</em>iver enzymes</strong>, and <strong><em>l</em>ow <em>p</em>latelets</strong>, dubbed the <strong><em>HELLP syndrome</em>.</strong></span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Retroplacental hemorrhage </strong>is <strong>not a part of HELLP syndrome</strong>. It refers to <strong>bleeding that occurs behind the placenta</strong>, which is often associated with conditions like placental abruption but not directly related to HELLP syndrome.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: Hemolysis:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a <strong>component of HELLP syndrome</strong>. It can be confirmed by laboratory findings such as anemia, elevated lactate dehydrogenase (LDH), and the presence of schistocytes on peripheral smear.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B: Elevated liver enzymes:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated liver enzymes, including <strong>aspartate aminotransferase </strong>(AST) and <strong>alanine aminotransferase </strong>(ALT), are represented by the <strong>EL in HELLP</strong>. They reflect hepatic injury, which is part of this syndrome.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C: Thrombocytopenia:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>LP in HELLP </strong>stands for <strong>low platelets</strong>, this can result in an increased risk of bleeding.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>HELLP syndrome </strong>is characterized by <strong>Hemolysis, Elevated Liver enzymes</strong>, and <strong>Low Platelet count</strong>, and does <strong>not </strong>include <strong>retroplacental hemorrhage </strong>as a component.</span></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10th/ 870</span></span></strong></span></span></p>",
    "correct_choice_id": 59847,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "CriteriaBased",
      "Factual"
    ]
  },
  {
    "id": 16869,
    "choices": [
      {
        "id": 67436,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Angiosarcoma</span></span></span></p>"
      },
      {
        "id": 67437,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leiomyoma</span></span></span></p>"
      },
      {
        "id": 67438,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Leiomyosarcoma</span></span></span></p>"
      },
      {
        "id": 67439,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rhabdomyoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with chronic pelvic pain undergoes a hysterectomy. The resected uterus is filled with nodules composed of benign smooth muscle cells. Which of the following terms best describes these nodules?</span></span></p>",
    "unique_key": "Q8965758",
    "question_audio": null,
    "question_video": null,
    "map_id": 32449,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Leiomyoma </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Leiomyomas </strong>(also known as uterine fibroids) are <strong>benign tumors </strong>arising from the <strong>smooth muscle cells of the uterus</strong>. They are the <strong>most common tumors </strong>of the <strong>uterus </strong>and are often <strong>found incidentally </strong>during a <strong>hysterectomy </strong>for various reasons, including <strong>chronic pelvic pain</strong>. <strong>Leiomyomas </strong>are <strong>composed of benign smooth muscle cells </strong>and are generally <strong>non-cancerous</strong>. They can cause symptoms such as <strong>pelvic pain</strong>, <strong>heavy menstrual bleeding</strong>, and <strong>pressure on adjacent organs</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Angiosarcoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This term <strong>refers to a malignant tumor </strong>derived from <strong>blood vessels</strong>, not smooth muscle.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Leiomyosarcoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This term refers to a <strong>malignant smooth muscle tumor</strong>, and the description in the question indicates benign nodules.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Rhabdomyoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This term refers to a <strong>benign tumor derived from striated muscle</strong>, not smooth muscle.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Leiomyomas </strong>are <strong>benign neoplasms </strong>originating from the <strong>myometrium </strong>and are <strong>commonly referred to as uterine fibroids</strong>. They are the <strong>most prevalent benign gynecological tumors </strong>in <strong>women of reproductive age </strong>and are often associated with symptoms like <strong>chronic pelvic pain</strong>, <strong>abnormal uterine bleeding</strong>, and <strong>reproductive dysfunction</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1021</span></strong></span></span></p>",
    "correct_choice_id": 67437,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "InvestigationBased"
    ]
  },
  {
    "id": 16873,
    "choices": [
      {
        "id": 67452,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clear cell</span></span></span></p>"
      },
      {
        "id": 67453,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma</span></span></span></p>"
      },
      {
        "id": 67454,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Squamous cell carcinoma</span></span></span></p>"
      },
      {
        "id": 67455,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transitional cell carcinoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common subtype of endometrial carcinoma on histopathology is:</span></span></p>",
    "unique_key": "Q7354322",
    "question_audio": null,
    "question_video": null,
    "map_id": 32447,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Adenocarcinoma </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>most common subtype</strong> of <strong>endometrial carcinoma. </strong>The <strong>majority of endometrial cancers </strong>are <strong>adenocarcinomas</strong>, and they are often <strong>classified into two main types</strong>: <strong>endometrioid </strong>and <strong>non-endometrioid</strong>. <strong>Endometrioid adenocarcinoma </strong>is the <strong>most common subtype</strong>, while <strong>clear cell</strong>, <strong>squamous cell</strong>, and <strong>transitional cell carcinomas </strong>are <strong>less common subtypes</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>majority of endometrial carcinomas </strong>are <strong>adenocarcinomas</strong>, with the <strong>endometrioid type </strong>being the <strong>most prevalent</strong>. It <strong>originates </strong>from the <strong>glandular tissue of the endometrium </strong>and often presents in <strong>postmenopausal women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Clear Cell:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clear cell carcinoma of the <strong>endometrium </strong>is a <strong>rare subtype </strong>and is typically associated with a <strong>more aggressive behavior </strong>and <strong>worse prognosis </strong>than endometrioid adenocarcinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Squamous Cell Carcinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Squamous cell carcinoma of the <strong>endometrium </strong>is <strong>exceedingly rare </strong>because the <strong>endometrium normally </strong>does <strong>not contain squamous cells</strong>; they may appear secondary to metaplastic processes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Transitional Cell Carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Transitional cell carcinoma is <strong>another rare subtype </strong>of <strong>endometrial cancer </strong>that <strong>resembles urothelial carcinoma of the bladder</strong>. This type of carcinoma is not commonly found in the endometrium.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:&nbsp; </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Adenocarcinoma</strong>, especially the <strong>endometrioid subtype</strong>, is the most <strong>common </strong>form of <strong>endometrial cancer</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 1010</span></strong></span></span></p>",
    "correct_choice_id": 67453,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  },
  {
    "id": 16875,
    "choices": [
      {
        "id": 67460,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Obesity </span></span></span></p>"
      },
      {
        "id": 67461,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Smoking</span></span></span></p>"
      },
      {
        "id": 67462,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Infertility </span></span></span></p>"
      },
      {
        "id": 67463,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tamoxifen</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Risk factor for endometrial carcinoma is all except:</span></span></span></p>",
    "unique_key": "Q8195104",
    "question_audio": null,
    "question_video": null,
    "map_id": 32450,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Smoking </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Endometrial carcinoma </strong>is associated with <strong>several risk factors</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Smoking, however</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, is <strong>not a well-established risk factor </strong>for <strong>endometrial carcinoma</strong>. It is&nbsp; likely due to its <strong>anti-estrogenic effects</strong>, which <strong>counteract the estrogen-driven proliferation </strong>of the <strong>endometrial lining</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Obesity:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Obese women have an <strong>increased risk of endometrial carcinoma</strong>, likely due to the <strong>excess production </strong>of <strong>estrogen </strong>in <strong>adipose tissue</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Infertility:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Infertile women, especially those with <strong>polycystic ovary syndrome </strong>(PCOS), are at an <strong>increased risk</strong>. This may be related to <strong>anovulation </strong>and <strong>unopposed estrogen stimulation</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Tamoxifen:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Tamoxifen, a <strong>selective estrogen receptor modulator </strong>(SERM) used in the <strong>treatment of breast cancer</strong>, has <strong>estrogenic effects </strong>on the <strong>endometrium </strong>and is associated with an <strong>increased risk of endometrial carcinoma</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Obesity</strong>, <strong>infertility</strong>, and the <strong>use of tamoxifen </strong>are known <strong>risk factors </strong>for developing <strong>endometrial carcinoma</strong>. In contrast, <strong>smoking </strong>has been <strong>associated with a decreased risk of endometrial carcinoma</strong>, likely due to its <strong>anti-estrogenic effects</strong>, which <strong>counteract </strong>the <strong>estrogen-driven proliferation </strong>of the <strong>endometrial lining</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1012</span></strong></span></span></p>",
    "correct_choice_id": 67461,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 41591,
    "choices": [
      {
        "id": 166052,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></p>"
      },
      {
        "id": 166053,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma</span></span></span></p>"
      },
      {
        "id": 166054,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma</span></span></span></p>"
      },
      {
        "id": 166055,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal carcinoma in situ (DCIS)</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman undergoes a breast biopsy after a suspicious mammogram. Histological examination reveals a tumor with lack of tubule formation, discohesive cells and a low mitotic rate. Immunohistochemistry shows positive estrogen receptor (ER) and progesterone receptor (PR) staining. What is the most likely histological type of breast cancer?</span></span></span></p>",
    "unique_key": "Q6982660",
    "question_audio": null,
    "question_video": null,
    "map_id": 32514,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Invasive lobular carcinoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(ILC) is characterized by a <strong>lack of tubule formation</strong>, <strong>discohesive cells </strong>that <strong>infiltrate the stroma in a single-file pattern</strong>, and a <strong>low mitotic rate</strong>. <strong>ILC </strong>is often <strong>ER and PR positive</strong>. The classic <strong>histological features </strong>include a <strong>targetoid appearance</strong>, known as <strong>&quot;Indian file&quot; pattern</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive ductal carcinoma</strong> tends to form <strong>glandular structures </strong>and does not usually present with the &quot;Indian file&quot; pattern of cell arrangement seen in invasive lobular carcinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Medullary carcinoma</strong> has a <strong>higher mitotic rate </strong>and a <strong>lymphocytic infiltrate</strong>, which differs from the low mitotic rate and discohesive cells described in the biopsy report.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Ductal carcinoma</strong> <strong>in situ</strong> represents an <strong>early form of breast cancer </strong>that is <strong>confined to the ducts </strong>and usually forms duct-like structures, unlike the pattern described.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive lobular carcinoma </strong>is characterized by the <strong>absence of tubule formation</strong>, <strong>discohesive cells</strong>, a <strong>low mitotic rate</strong>, and <strong>positive hormone receptor status</strong>.</span></span></span></p>",
    "correct_choice_id": 166053,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16877,
    "choices": [
      {
        "id": 67468,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apocrine DCIS</span></span></span></p>"
      },
      {
        "id": 67469,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neuroendocrine DCIS </span></span></span></p>"
      },
      {
        "id": 67470,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Will-differentiated DCIS </span></span></span></p>"
      },
      {
        "id": 67471,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Comedo DCIS</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 47-year-old woman presents for evaluation of a hard, poorly defined mass in her left breast. She reports no pain or discharge, but she has noted a recent change in the shape of the breast. There is no family history of breast cancer. A mammogram reveals microcalcifications in the upper outer quadrant of the left breast. A biopsy of the lesion is performed. </span></span><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The type of mammary ductal carcinoma in situ (DCIS) most likely to result in a palpable abnormality in the breast is:</span></span></p>",
    "unique_key": "Q9019592",
    "question_audio": null,
    "question_video": null,
    "map_id": 32509,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Comedo DCIS </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">DCIS&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">most frequently presents as <strong>mammographic calcifications</strong>. Less typically DCIS may present as a <strong><em>vaguely palpable mass</em></strong>. This is most likely with <strong><em>Comedocarcinomas</em></strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Comedo DCIS </strong>often <strong>presents with high-grade necrotic cells </strong>and <strong>dystrophic calcifications</strong>, which can be <strong>detected on mammography </strong>and may also <strong>form a palpable mass</strong>, consistent with the patient&rsquo;s presentation.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Apocrine DCIS</strong> presents with <strong>characteristic apocrine cytologic features under microscopy </strong>but is not the most likely to form a palpable mass.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Neuroendocrine DCIS</strong> is a <strong>rare form </strong>and typically does not present as a palpable lesion in the breast.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Well-differentiated DCIS</strong> may <strong>show microcalcifications </strong>on <strong>mammography</strong>, but palpable masses are less common than in the comedo subtype.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Comedo DCIS </strong>is most likely to <strong>present as a palpable mass </strong>due to the <strong>associated necrosis </strong>and <strong>calcifications</strong>. It is often <strong>found on mammography </strong>and can <strong>form a more solid</strong>, <strong>palpable lesion </strong>compared to other subtypes of DCIS.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1060</span></strong></span></span></p>",
    "correct_choice_id": 67471,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 16881,
    "choices": [
      {
        "id": 67484,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nottingham</span></span></span></p>"
      },
      {
        "id": 67485,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Birmingham</span></span></span></p>"
      },
      {
        "id": 67486,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cunningham</span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;</span></span></span></p>"
      },
      {
        "id": 67487,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Welham</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All invasive breast carcinomas are graded histologically with the following scoring system:</span></span></p>",
    "unique_key": "Q4197855",
    "question_audio": null,
    "question_video": null,
    "map_id": 32510,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nottingham</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Breast carcinomas </strong>are histologically graded using the <strong>Nottingham Histologic Score</strong>, also known as the <strong>Nottingham Combined Histologic Grade </strong>or <strong>Nottingham Grading System</strong>. This system evaluates <strong>three histologic features</strong>: <strong>tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>. Each component is assigned a score, and the scores are combined to determine the overall grade. This grading system helps in predicting the behavior and prognosis of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Nottingham Histologic Score </strong>is used for <strong>grading breast carcinomas</strong>. It <strong>assesses tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>, each of which is given a score.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1064</span></strong></span></span></p>",
    "correct_choice_id": 67484,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 41588,
    "choices": [
      {
        "id": 166040,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polymerase Chain Reaction (PCR)</span></span></span></p>"
      },
      {
        "id": 166041,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluorescence In Situ Hybridization (FISH)</span></span></span></p>"
      },
      {
        "id": 166042,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Southern Blotting</span></span></span></p>"
      },
      {
        "id": 166043,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Western Blotting</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 55-year-old woman presents with a suspicious breast mass. A core biopsy is performed, and immunohistochemistry (IHC) reveals a HER2/neu score of 2. Given the equivocal HER2 status, which technique is most appropriate for further evaluation to determine the HER2/neu gene amplification status?</span></span></p>",
    "unique_key": "Q9082804",
    "question_audio": null,
    "question_video": null,
    "map_id": 32511,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>B)</strong> <strong>Fluorescence In Situ Hybridization (FISH)</strong></span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluorescence In Situ Hybridization (FISH)&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong>molecular cytogenetic technique </strong>that can be used to <strong>detect and quantify the presence of specific DNA sequences</strong>. In the context of breast cancer, FISH is commonly used to assess the amplification of the HER2/neu gene. <strong><em>A HER2/neu score of 2 by IHC is considered equivocal, and FISH is recommended to further evaluate the gene amplification status</em></strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Polymerase Chain Reaction (PCR</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">) is a <strong>technique </strong>used to <strong>amplify DNA </strong>but is not typically employed to assess gene amplification status. It is more suitable for studying the presence or absence of specific DNA sequences.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Southern blotting</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a technique used to <strong>detect specific DNA sequences </strong>in a <strong>DNA sample</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Western blotting</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a technique used to <strong>detect specific proteins in a sample</strong>. It is not applicable to assess gene amplification and is more suited for protein analysis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In cases of <strong>equivocal HER2/neu IHC </strong>results which is <strong>IHC score of 2</strong>, further recommended technique is <strong>Fluorescence In Situ Hybridization </strong>(FISH) for evaluation of <strong>HER2/neu gene amplification status </strong>in <strong>breast cancer</strong>.</span></span></span></p>",
    "correct_choice_id": 166041,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 41589,
    "choices": [
      {
        "id": 166044,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate hormonal therapy with tamoxifen</span></span></span></p>"
      },
      {
        "id": 166045,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer chemotherapy with doxorubicin and cyclophosphamide</span></span></span></p>"
      },
      {
        "id": 166046,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prescribe trastuzumab </span></span></span></p>"
      },
      {
        "id": 166047,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recommend radiotherapy for local control</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with a palpable lump in her left breast. A biopsy is performed, and the histopathological examination reveals invasive ductal carcinoma. Immunohistochemistry (IHC) shows a HER2/neu score of 3+. What is the most appropriate next step in managing this patient&#39;s breast cancer?</span></span></p>",
    "unique_key": "Q6733957",
    "question_audio": null,
    "question_video": null,
    "map_id": 32512,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Prescribe trastuzumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, given its <strong>ability to target HER2/neu-positive tumors</strong>, would be the most appropriate <strong>next step in management </strong>for a patient with a HER2/neu score of 3+ on IHC.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>hormonal therapy </strong>is an essential part of the <strong>treatment for hormone receptor-positive breast cancer</strong>, the HER2/neu status of the tumor guides the use of targeted therapies such as trastuzumab.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chemotherapy </strong>may be a <strong>component of treatment for breast cancer, </strong>but for HER2/neu-positive tumors, trastuzumab is a key targeted therapy that has been shown to significantly improve outcomes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Radiotherapy </strong>could be part of the <strong>comprehensive treatment for breast cancer</strong>, particularly for local control, but is not directly related to the HER2/neu overexpression finding.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient with a <strong>HER2/neu score of 3+ indicating HER2 protein overexpression</strong>, <strong>trastuzumab </strong>is the most appropriate next step for targeted therapy in the management of HER2-positive breast cancer.</span></span></span></p>",
    "correct_choice_id": 166046,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 41590,
    "choices": [
      {
        "id": 166048,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An aromatase inhibitor </span></span></span></p>"
      },
      {
        "id": 166049,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective estrogen receptor modulator (SERM) like tamoxifen</span></span></span></p>"
      },
      {
        "id": 166050,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-releasing hormone agonist</span></span></span></p>"
      },
      {
        "id": 166051,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progestin therapy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old postmenopausal woman is diagnosed with estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) invasive lobular carcinoma of the breast. What is the most appropriate adjuvant endocrine therapy for this patient?</span></span></p>",
    "unique_key": "Q4657524",
    "question_audio": null,
    "question_video": null,
    "map_id": 32513,
    "difficulty_level": "difficult",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) An aromatase inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For <strong>postmenopausal women </strong>with <strong>hormone receptor-positive breast cancer</strong>, <strong>aromatase inhibitors </strong>(e.g., letrozole, anastrozole, exemestane) are often preferred <strong>over tamoxifen</strong>. <strong>Aromatase inhibitors reduce </strong>the <strong>production of estrogen </strong>and are associated with <strong>improved disease-free survival </strong>in this <strong>population</strong>. <strong>Tamoxifen </strong>is more commonly used in <strong>premenopausal women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitors</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are typically the <strong>first choice for ER+ breast cancer </strong>in <strong>postmenopausal women </strong>because they are <strong>effective at reducing the amount of estrogen </strong>produced by <strong>adipose </strong>and <strong>other tissues</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tamoxifen, a SERM</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, can be <strong>used in postmenopausal women </strong>but is often reserved for those who <strong>cannot tolerate aromatase inhibitors </strong>or for premenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Gonadotropin-releasing</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>hormone agonists</strong> are used in <strong>premenopausal women </strong>to <strong>suppress ovarian estrogen production</strong>, which is not applicable in postmenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Progestin therapy</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not typically used in the treatment of <strong>hormone receptor-positive breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>postmenopausal woman </strong>with <strong>ER+ and PR+ breast cancer</strong>, the most appropriate adjuvant <strong>endocrine therapy </strong>is an <strong>aromatase inhibitor</strong>, which has been shown to be more <strong>effective than tamoxifen </strong>in this patient population.</span></span></span></p>",
    "correct_choice_id": 166048,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 41592,
    "choices": [
      {
        "id": 166056,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></p>"
      },
      {
        "id": 166057,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenoma</span></span></span></p>"
      },
      {
        "id": 166058,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal carcinoma in situ (DCIS)</span></span></span></p>"
      },
      {
        "id": 166059,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Phylloides tumor</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 28-year-old woman presents with a painless breast lump that has been gradually increasing in size over the past few months. On examination, a well-defined, mobile, rubbery mass is palpable in the upper outer quadrant of her left breast. Mammography reveals a well-circumscribed, round mass without microcalcifications. What is the most likely diagnosis?</span></span></p>",
    "unique_key": "Q7688906",
    "question_audio": null,
    "question_video": null,
    "map_id": 32515,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Fibroadenoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fibroadenomas&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are common <strong>benign breast tumors </strong>in <strong>young women</strong>. They are typically <strong>well-circumscribed</strong>, <strong>mobile</strong>, and <strong>rubbery </strong>on <strong>palpation</strong>. <strong>Mammography </strong>shows a <strong>round mass without microcalcifications</strong>. They are hormonally responsive and may fluctuate in size during the menstrual cycle. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Invasive Ductal Carcinoma (IDC):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">it is the </span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">most common type of breast cancer. It often presents as an irregularly shaped mass with spiculated margins on imaging. Microcalcifications are a common finding in IDC. Unlike fibroadenomas, IDC tends to infiltrate surrounding tissues invasively.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Ductal Carcinoma in Situ (DCIS):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">it is a </span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>non-invasive condition </strong>where <strong>abnormal cells are found in the lining </strong>of a <strong>breast duct </strong>but have not invaded surrounding tissues. It is usually detected through mammography and does not typically present as a palpable mass. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Phylloides Tumor&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">are <strong>rare fibroepithelial tumors </strong>that may <strong>mimic fibroadenomas clinically</strong>. They are typically <strong>larger </strong>than <strong>fibroadenomas </strong>and may have a <strong>leaf-like appearance on imaging</strong>. Phylloides tumors have a potential for rapid growth and a higher risk of recurrence compared to fibroadenomas.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Fibroadenoma </strong>is the most likely diagnosis for a <strong>young woman </strong>presenting with a <strong>well-defined, mobile, rubbery breast mass </strong>and a <strong>mammogram </strong>showing a <strong>well-circumscribed, non-calcified round lesion.</strong></span></span></span></p>",
    "correct_choice_id": 166057,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 16860,
    "choices": [
      {
        "id": 67400,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">6 </span></span></span></p>"
      },
      {
        "id": 67401,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">11</span></span></span></p>"
      },
      {
        "id": 67402,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">18 </span></span></span></p>"
      },
      {
        "id": 67403,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">32</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female presented in the gynecology OPD with the presentation as given in the image. The examination revealed presence of high-risk HPV. Which of the following is the causative agent?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/05/28/untitled-547.jpg\" style=\"height:253px; width:300px\" /></span></span></p>",
    "unique_key": "Q4169318",
    "question_audio": null,
    "question_video": null,
    "map_id": 32516,
    "difficulty_level": "beginner",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 18 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The question has an image showing <strong>multiple vagino-cervical warts</strong>. If we read the stem of the question, it makes a mention of <strong>high-risk HPV subtype</strong> and so, the answer is <strong>HPV 16</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HPV 18</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>correct answer</strong>. It is one of the <strong>high-risk HPV types </strong>known to be associated with <strong>cervical cancer </strong>and <strong>high-grade dysplasia</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. HPV 6</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is incorrect because it is <strong>associated with low-risk lesions </strong>such as <strong>genital warts </strong>rather than high-risk cervical pathologies.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. HPV 11</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is also incorrect for the <strong>same reason as HPV 6</strong>; it is linked to benign lesions and not high-risk cervical dysplasias or cancers.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. HPV 32</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not typically <strong>implicated in high-risk cervical disease</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>HPV 16 </strong>and <strong>18 are involved in the pathogenesis </strong>of <strong>high-grade cervical dysplasias </strong>and <strong>cervical cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1001</span></strong></span></span></p>",
    "correct_choice_id": 67402,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "ImageBased"
    ]
  },
  {
    "id": 16867,
    "choices": [
      {
        "id": 67428,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood vessel penetration by tumor cells</span></span></span></p>"
      },
      {
        "id": 67429,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor cells in lymphatic channels</span></span></span></p>"
      },
      {
        "id": 67430,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphocyte infiltration </span></span></span></p>"
      },
      {
        "id": 67431,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">With regard to the malignant behavior of leiomyosarcoma, the most important criterion is:</span></span></p>",
    "unique_key": "Q8762571",
    "question_audio": null,
    "question_video": null,
    "map_id": 32508,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) The number of mitoses per high power field </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most important criterion</strong> for <strong>distinction of leiomyosarcoma </strong>from <strong>leiomyoma </strong>(malignant transformation) is the <strong>number of mitoses present</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ten high power fields </strong>(hpf) are <strong>examined</strong>. If<strong> &gt; 10 mitoses</strong> are seen, it <strong>signifies malignancy</strong>. If <strong>cellular atypia </strong>is also <strong>present</strong>, <strong>&gt; 5 mitoses </strong>are enough to make a <strong>diagnosis of leiomyosarcoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When <strong>distinguishing leiomyosarcoma from leiomyoma</strong>, the <strong>assessment of malignancy </strong>heavily <strong>relies on histological examination</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a key <strong>histological criterion </strong>to determine the <strong>malignant behavior of leiomyosarcoma</strong>. A higher number of mitotic figures usually indicates a more aggressive tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Blood vessel penetration by tumor cells</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>feature observed in malignant tumors</strong>. However, while significant, it is not the most critical factor in diagnosing leiomyosarcoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. The presence of tumor cells in lymphatic channels</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is another <strong>indication of potential malignancy </strong>and can signify the spread of cancer, but it&#39;s not the primary criterion for diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Lymphocyte infiltration</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is often a <strong>sign of an immune response to the tumor </strong>rather than a direct indication of malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>high mitotic index </strong>is indicative of <strong>aggressive tumor behavior </strong>and <strong>malignancy</strong>, aiding in the <strong>differentiation between benign </strong>and <strong>malignant smooth muscle tumors </strong>such as <strong>leiomyomas </strong>and <strong>leiomyosarcomas</strong>, respectively. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1021</span></strong></span></span></p>",
    "correct_choice_id": 67431,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 41591,
    "choices": [
      {
        "id": 166052,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive ductal carcinoma</span></span></span></p>"
      },
      {
        "id": 166053,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma</span></span></span></p>"
      },
      {
        "id": 166054,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary carcinoma</span></span></span></p>"
      },
      {
        "id": 166055,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ductal carcinoma in situ (DCIS)</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman undergoes a breast biopsy after a suspicious mammogram. Histological examination reveals a tumor with lack of tubule formation, discohesive cells and a low mitotic rate. Immunohistochemistry shows positive estrogen receptor (ER) and progesterone receptor (PR) staining. What is the most likely histological type of breast cancer?</span></span></span></p>",
    "unique_key": "Q6982660",
    "question_audio": null,
    "question_video": null,
    "map_id": 32339,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Invasive lobular carcinoma</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive lobular carcinoma&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(ILC) is characterized by a <strong>lack of tubule formation</strong>, <strong>discohesive cells </strong>that <strong>infiltrate the stroma in a single-file pattern</strong>, and a <strong>low mitotic rate</strong>. <strong>ILC </strong>is often <strong>ER and PR positive</strong>. The classic <strong>histological features </strong>include a <strong>targetoid appearance</strong>, known as <strong>&quot;Indian file&quot; pattern</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive ductal carcinoma</strong> tends to form <strong>glandular structures </strong>and does not usually present with the &quot;Indian file&quot; pattern of cell arrangement seen in invasive lobular carcinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option C.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Medullary carcinoma</strong> has a <strong>higher mitotic rate </strong>and a <strong>lymphocytic infiltrate</strong>, which differs from the low mitotic rate and discohesive cells described in the biopsy report.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">.&nbsp;<strong>Ductal carcinoma</strong> <strong>in situ</strong> represents an <strong>early form of breast cancer </strong>that is <strong>confined to the ducts </strong>and usually forms duct-like structures, unlike the pattern described.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong> </span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Invasive lobular carcinoma </strong>is characterized by the <strong>absence of tubule formation</strong>, <strong>discohesive cells</strong>, a <strong>low mitotic rate</strong>, and <strong>positive hormone receptor status</strong>.</span></span></span></p>",
    "correct_choice_id": 166053,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 13634,
    "choices": [
      {
        "id": 54497,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17p </span></span></span></span></p>"
      },
      {
        "id": 54498,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17q </span></span></span></span></p>"
      },
      {
        "id": 54499,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">13q </span></span></span></span></p>"
      },
      {
        "id": 54500,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">13p</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 46-year-old female presents to her family physician because she palpated a nodule in her left breast during a breast self-examination. She subsequently undergoes a partial mastectomy. The mass is examined by a pathologist who makes a diagnosis of invasive ductal carcinoma. Subsequent genetic testing reveals a mutation of the BRCA2 gene. Of the following, what is the location for this mutation?</span></span></p>",
    "unique_key": "Q5346615",
    "question_audio": null,
    "question_video": null,
    "map_id": 32329,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 13q</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">13q&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">indicates the <strong>long arm of chromosome 13</strong>, which is the correct location for the <strong>BRCA2 gene </strong>associated with <strong>breast cancer.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.&nbsp;</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>17p</strong> refers to the <strong>short arm of chromosome 17</strong>, which is where the gene for the <strong>p53 protein </strong>is located,<strong> not BRCA2</strong>. p53 is commonly mutated in many forms of cancer.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>17q</strong> refers to the <strong>long arm of chromosome 17. </strong>This is the <strong>location of the BRCA1 gene</strong>, not BRCA2.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12pt\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span></span><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>13p</strong> would refer to the<strong> short arm of chromosome 13</strong>, which is <strong>not </strong>the correct location for the <strong>BRCA2 gene.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The<strong> BRCA2 gene </strong>is located on the<strong> long arm of chromosome 13</strong>, at the <strong>cytogenetic band 13q</strong>.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u></strong><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> ed/ 293-4</span></span></strong></span></span></p>",
    "correct_choice_id": 54499,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 13640,
    "choices": [
      {
        "id": 54521,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibition of cell proliferation </span></span></span></span></p>"
      },
      {
        "id": 54522,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Promotion of apoptosis </span></span></span></span></p>"
      },
      {
        "id": 54523,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stimulation of angiogenesis </span></span></span></span></p>"
      },
      {
        "id": 54524,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Activation of cell signaling pathways</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45-year-old woman is diagnosed with breast cancer, and her tumor cells demonstrate overexpression of the HER2/neu proto-oncogene. What is the primary mechanism by which HER2/neu contributes to the pathophysiology of her cancer?</span></span></p>",
    "unique_key": "Q5079178",
    "question_audio": null,
    "question_video": null,
    "map_id": 32331,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Activation of cell signaling pathways</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Proto-oncogene HER2/neu </strong>encodes for a protein that is a <strong>receptor for growth factors</strong>. Its <strong>over-expression </strong>can lead to excessive activation of <strong>downstream cell signaling pathways</strong>, including the<strong> PI3K/Akt and MAPK/Erk pathways</strong>, which promote <strong>cell proliferation and survival</strong>. <strong>HER2/neu overexpression </strong>is associated with a <strong>more aggressive breast cancer phenotype and poorer prognosis.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>HER2/neu </strong>is a receptor <strong>tyrosine kinase </strong>that, when<strong> overexpressed</strong>, results in the excessive <strong>activation of downstream signaling pathways</strong>, including <strong>PI3K/Akt and MAPK/Erk</strong>, that are known to<strong> promote cell proliferation and survival.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>&nbsp;Inhibition of cell proliferation </strong>is <strong>not </strong>associated with<strong> HER2/neu overexpression; </strong>instead, <strong>HER2/neu </strong>leads to <strong>increased cell proliferation</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;<strong>Promotion of apoptosis </strong>is <strong>not </strong>a mechanism of<strong> HER2/neu action</strong>. In contrast,<strong> HER2/neu overexpression </strong>tends to confer <strong>resistance to apoptotic signals</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C.</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While <strong>HER2/neu </strong>overexpression can have d<strong>ownstream effects </strong>that might<strong> indirectly promote angiogenesis</strong>, this is <strong>not the primary action of the proto-oncogene.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Overexpression of the HER2/neu proto-oncogene in breast cancer </strong>leads to the activation of <strong>cell signaling pathways </strong>that promote <strong>cell proliferation and survival. </strong>This overexpression is associated with a<strong> more aggressive disease phenotype and a poorer prognosis</strong>. <strong>Targeted </strong>therapies <strong>against HER2/neu </strong>can be effective in <strong>treating tumors with this over-expression</strong>.</span></span></span></span></p>",
    "correct_choice_id": 54524,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 13648,
    "choices": [
      {
        "id": 54553,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a proto-oncogene</span></span></span></span></p>"
      },
      {
        "id": 54554,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is involved in cell cycle regulation</span></span></span></span></p>"
      },
      {
        "id": 54555,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a tumor suppressor gene</span></span></span></span></p>"
      },
      {
        "id": 54556,
        "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is not involved in breast cancer</span></span></span></span></p>"
      }
    ],
    "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with a history of breast cancer. They undergo genetic testing, which reveals a mutation in the BRCA1 gene. Which of the following is true about BRCA1? </span></span></p>",
    "unique_key": "Q8350724",
    "question_audio": null,
    "question_video": null,
    "map_id": 32334,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) It is a tumor suppressor gene</span></span></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></span></strong></span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA1&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">is a <strong><em>tumor suppressor gene</em></strong> that encodes for a protein involved in<strong> DNA repair</strong>.<strong> Mutations in the BRCA1 gene </strong>are associated with an<strong> increased risk </strong>of developing<strong><em> breast and ovarian cancers</em></strong>. The<strong> protein </strong>produced by the <strong>BRCA1 gene </strong>is involved in<strong> repairing DNA damage and preventing the formation of tumors</strong>.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is a tumor suppressor gene.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>BRCA1 </strong>is a tumor suppressor gene that <strong>encodes for a protein involved in DNA repair</strong>.<strong> Mutations </strong>in this gene can lead to<strong> an increased risk of developing breast and ovarian cancers </strong>due to the<strong> loss of effective DNA damage repair</strong>, which can result in the <strong>accumulation of mutations </strong>that contribute to<strong> tumor formation.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. It is a proto-oncogene.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proto-oncogenes are <strong>genes </strong>that normally help <strong>cells grow</strong>. When a <strong>proto-oncogene mutates or becomes overactive</strong>, it becomes an<strong> oncogene </strong>and can<strong> lead to cancer</strong>.<strong> BRCA1</strong>, however, is known as a<strong> tumor suppressor gene</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. It is involved in cell cycle regulation.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While the <strong>BRCA1 gene </strong>does play a role in <strong>cell cycle regulation </strong>as part of its<strong> function </strong>in response to<strong> DNA damage</strong>, it is<strong> more </strong>specifically characterized as a<strong> gene </strong>involved in<strong> DNA repair pathways, </strong>particularly <strong>double-strand break repair</strong>.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. It is not involved in breast cancer.&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This statement is <strong>incorrect </strong>as mutations in the<strong> BRCA1 gene are well-established risk factors </strong>for<strong> breast cancer</strong>, as well as <strong>ovarian cancer.</strong></span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><u><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></u></strong></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>BRCA1 gene </strong>is a<strong> tumor suppressor gene </strong>involved in <strong>DNA repair</strong>. <strong>Mutations in BRCA1 </strong>increase the<strong> risk of breast and ovarian cancers </strong>by impairing the repair of DNA damage, which<strong> prevents </strong>the<strong> proper regulation of cell growth and division, </strong>thereby contributing to <strong>tumorigenesis.</strong></span></span></span></span></p>",
    "correct_choice_id": 54555,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16879,
    "choices": [
      {
        "id": 67476,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">p53 </span></span></span></p>"
      },
      {
        "id": 67477,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA-1</span></span></span></p>"
      },
      {
        "id": 67478,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retinoblastoma (Rb)</span></span></span></p>"
      },
      {
        "id": 67479,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">H-Ras</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased susceptibility to sporadic breast cancer is likely to be associated with a mutation in the following gene?</span></span></p>",
    "unique_key": "Q9670837",
    "question_audio": null,
    "question_video": null,
    "map_id": 32333,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) p53 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Breast cancer </strong>can be either <strong>familial </strong>(associated with germline mutation) or <strong>sporadic </strong>(associated with somatic mutation).</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>p53 gene</strong>, known for its <strong>role in cell cycle control </strong>and <strong>apoptosis</strong>, is associated with <strong>Li-Fraumeni syndrome</strong>. This <strong>hereditary condition </strong>predisposes <strong>individuals to a variety of cancers</strong>, including <strong>breast cancer</strong>, at an <strong>early age</strong>.&nbsp;</span><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Sporadic breast cancer&nbsp;</span></strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">is associated with mutation in <strong>p53 gene</strong> (p53 defect is present in 40% of human breast cancer as an acquired defect) and <strong>PTEN gene</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Since, <strong>incidence of sporadic cancer </strong>is much <strong>more than familial cancer</strong>, so the most <strong>important gene mutation increasing susceptibility </strong>to <strong>breast cancer </strong>should be answered as p53.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The <strong>BRCA1 gene mutation </strong>carries a <strong>high risk for developing breast </strong>and <strong>ovarian cancers</strong>. Individuals with this mutation have a lifetime risk of breast cancer that is significantly higher than the general population.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. While the <strong>Rb gene </strong>is crucial in <strong>controlling cell proliferation </strong>and its <strong>mutation </strong>is primarily <strong>associated with retinoblastoma</strong>, it is not a leading cause of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>H-Ras </strong>is <strong>part of the Ras gene family</strong>; while <strong>mutations </strong>in these <strong>genes can lead to cancer</strong>, they are not typically associated with hereditary breast cancer syndromes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>p53 gene mutation </strong>is </span><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">the <strong>most important gene mutation increasing susceptibility </strong>to <strong>breast cancer</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></span></u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1051</span></span></strong></p>",
    "correct_choice_id": 67476,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 16880,
    "choices": [
      {
        "id": 67480,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">p53 </span></span></span></p>"
      },
      {
        "id": 67481,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA-2</span></span></span></p>"
      },
      {
        "id": 67482,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Her 2/Neu gene</span></span></span></p>"
      },
      {
        "id": 67483,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">C-myc gene</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A female patient presented with a firm mass of 2 &times; 2 cm in the upper outer quadrant of the breast. She gives a family history of ovarian carcinoma. The investigation that needs to be done to assess for mutations is:</span></span></p>",
    "unique_key": "Q4760592",
    "question_audio": null,
    "question_video": null,
    "map_id": 32335,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) BRCA2 </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">BRCA2</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>tumor suppressor gene</strong>, and <strong>mutations in this gene </strong>are known to significantly <strong>increase the risk of both breast </strong>and <strong>ovarian cancers </strong>in bwith a history suggestive of <strong>hereditary breast </strong>and <strong>ovarian cancer syndrome</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>The p53 gene</strong>, when <strong>mutated</strong>, can lead to a <strong>variety of cancers</strong>; however, in the context of a family history suggesting a hereditary breast and ovarian cancer syndrome, BRCA1 and BRCA2 gene testing is more directly relevant.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">. <strong>Her 2/Neu gene</strong> amplification is <strong>associated with breast cancer aggressiveness </strong>and <strong>treatment decisions </strong>but is not a part of routine genetic screening for hereditary breast and ovarian cancer syndrome.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>C-myc</strong> is an <strong>oncogene implicated </strong>in the <strong>pathogenesis of various cancers</strong>, including <strong>breast cancer</strong>, but it does not have a direct role in hereditary breast and ovarian cancer syndromes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>BRCA2 genetic testing </strong>is indicated in a patient with a <strong>breast mass </strong>and a <strong>family history of ovarian carcinoma</strong>, as <strong>mutations </strong>in the <strong>BRCA1 and BRCA2 genes </strong>are strongly associated with <strong>hereditary breast </strong>and <strong>ovarian cancer syndromes</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1058</span></strong></span></span></p>",
    "correct_choice_id": 67481,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "DiagnosisBased"
    ]
  },
  {
    "id": 16881,
    "choices": [
      {
        "id": 67484,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Nottingham</span></span></span></p>"
      },
      {
        "id": 67485,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Birmingham</span></span></span></p>"
      },
      {
        "id": 67486,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cunningham</span></span></span><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;</span></span></span></p>"
      },
      {
        "id": 67487,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Welham</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All invasive breast carcinomas are graded histologically with the following scoring system:</span></span></p>",
    "unique_key": "Q4197855",
    "question_audio": null,
    "question_video": null,
    "map_id": 32336,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Nottingham</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A: </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Breast carcinomas </strong>are histologically graded using the <strong>Nottingham Histologic Score</strong>, also known as the <strong>Nottingham Combined Histologic Grade </strong>or <strong>Nottingham Grading System</strong>. This system evaluates <strong>three histologic features</strong>: <strong>tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>. Each component is assigned a score, and the scores are combined to determine the overall grade. This grading system helps in predicting the behavior and prognosis of breast cancer.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>Nottingham Histologic Score </strong>is used for <strong>grading breast carcinomas</strong>. It <strong>assesses tubule formation</strong>, <strong>nuclear pleomorphism</strong>, and <strong>mitotic count</strong>, each of which is given a score.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1064</span></strong></span></span></p>",
    "correct_choice_id": 67484,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "Factual"
    ]
  },
  {
    "id": 41589,
    "choices": [
      {
        "id": 166044,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate hormonal therapy with tamoxifen</span></span></span></p>"
      },
      {
        "id": 166045,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Administer chemotherapy with doxorubicin and cyclophosphamide</span></span></span></p>"
      },
      {
        "id": 166046,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prescribe trastuzumab </span></span></span></p>"
      },
      {
        "id": 166047,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Recommend radiotherapy for local control</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old woman presents with a palpable lump in her left breast. A biopsy is performed, and the histopathological examination reveals invasive ductal carcinoma. Immunohistochemistry (IHC) shows a HER2/neu score of 3+. What is the most appropriate next step in managing this patient&#39;s breast cancer?</span></span></p>",
    "unique_key": "Q6733957",
    "question_audio": null,
    "question_video": null,
    "map_id": 32337,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Prescribe trastuzumab</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trastuzumab</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, given its <strong>ability to target HER2/neu-positive tumors</strong>, would be the most appropriate <strong>next step in management </strong>for a patient with a HER2/neu score of 3+ on IHC.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While <strong>hormonal therapy </strong>is an essential part of the <strong>treatment for hormone receptor-positive breast cancer</strong>, the HER2/neu status of the tumor guides the use of targeted therapies such as trastuzumab.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Chemotherapy </strong>may be a <strong>component of treatment for breast cancer, </strong>but for HER2/neu-positive tumors, trastuzumab is a key targeted therapy that has been shown to significantly improve outcomes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D.&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Radiotherapy </strong>could be part of the <strong>comprehensive treatment for breast cancer</strong>, particularly for local control, but is not directly related to the HER2/neu overexpression finding.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For a patient with a <strong>HER2/neu score of 3+ indicating HER2 protein overexpression</strong>, <strong>trastuzumab </strong>is the most appropriate next step for targeted therapy in the management of HER2-positive breast cancer.</span></span></span></p>",
    "correct_choice_id": 166046,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual",
      "InvestigationBased"
    ]
  },
  {
    "id": 41590,
    "choices": [
      {
        "id": 166048,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An aromatase inhibitor </span></span></span></p>"
      },
      {
        "id": 166049,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Selective estrogen receptor modulator (SERM) like tamoxifen</span></span></span></p>"
      },
      {
        "id": 166050,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadotropin-releasing hormone agonist</span></span></span></p>"
      },
      {
        "id": 166051,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Progestin therapy</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old postmenopausal woman is diagnosed with estrogen receptor-positive (ER+) and progesterone receptor-positive (PR+) invasive lobular carcinoma of the breast. What is the most appropriate adjuvant endocrine therapy for this patient?</span></span></p>",
    "unique_key": "Q4657524",
    "question_audio": null,
    "question_video": null,
    "map_id": 32338,
    "difficulty_level": "difficult",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) An aromatase inhibitor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For <strong>postmenopausal women </strong>with <strong>hormone receptor-positive breast cancer</strong>, <strong>aromatase inhibitors </strong>(e.g., letrozole, anastrozole, exemestane) are often preferred <strong>over tamoxifen</strong>. <strong>Aromatase inhibitors reduce </strong>the <strong>production of estrogen </strong>and are associated with <strong>improved disease-free survival </strong>in this <strong>population</strong>. <strong>Tamoxifen </strong>is more commonly used in <strong>premenopausal women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Aromatase inhibitors</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> are typically the <strong>first choice for ER+ breast cancer </strong>in <strong>postmenopausal women </strong>because they are <strong>effective at reducing the amount of estrogen </strong>produced by <strong>adipose </strong>and <strong>other tissues</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Tamoxifen, a SERM</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, can be <strong>used in postmenopausal women </strong>but is often reserved for those who <strong>cannot tolerate aromatase inhibitors </strong>or for premenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Gonadotropin-releasing</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> <strong>hormone agonists</strong> are used in <strong>premenopausal women </strong>to <strong>suppress ovarian estrogen production</strong>, which is not applicable in postmenopausal women.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Progestin therapy</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not typically used in the treatment of <strong>hormone receptor-positive breast cancer</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a <strong>postmenopausal woman </strong>with <strong>ER+ and PR+ breast cancer</strong>, the most appropriate adjuvant <strong>endocrine therapy </strong>is an <strong>aromatase inhibitor</strong>, which has been shown to be more <strong>effective than tamoxifen </strong>in this patient population.</span></span></span></p>",
    "correct_choice_id": 166048,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16867,
    "choices": [
      {
        "id": 67428,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood vessel penetration by tumor cells</span></span></span></p>"
      },
      {
        "id": 67429,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tumor cells in lymphatic channels</span></span></span></p>"
      },
      {
        "id": 67430,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lymphocyte infiltration </span></span></span></p>"
      },
      {
        "id": 67431,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">With regard to the malignant behavior of leiomyosarcoma, the most important criterion is:</span></span></p>",
    "unique_key": "Q8762571",
    "question_audio": null,
    "question_video": null,
    "map_id": 32330,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) The number of mitoses per high power field </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<ul>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>most important criterion</strong> for <strong>distinction of leiomyosarcoma </strong>from <strong>leiomyoma </strong>(malignant transformation) is the <strong>number of mitoses present</strong>. </span></span></span></li>\r\n\t<li style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Ten high power fields </strong>(hpf) are <strong>examined</strong>. If<strong> &gt; 10 mitoses</strong> are seen, it <strong>signifies malignancy</strong>. If <strong>cellular atypia </strong>is also <strong>present</strong>, <strong>&gt; 5 mitoses </strong>are enough to make a <strong>diagnosis of leiomyosarcoma.</strong></span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When <strong>distinguishing leiomyosarcoma from leiomyoma</strong>, the <strong>assessment of malignancy </strong>heavily <strong>relies on histological examination</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The number of mitoses per high power field</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a key <strong>histological criterion </strong>to determine the <strong>malignant behavior of leiomyosarcoma</strong>. A higher number of mitotic figures usually indicates a more aggressive tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Blood vessel penetration by tumor cells</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a <strong>feature observed in malignant tumors</strong>. However, while significant, it is not the most critical factor in diagnosing leiomyosarcoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. The presence of tumor cells in lymphatic channels</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is another <strong>indication of potential malignancy </strong>and can signify the spread of cancer, but it&#39;s not the primary criterion for diagnosis.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Lymphocyte infiltration</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is often a <strong>sign of an immune response to the tumor </strong>rather than a direct indication of malignancy.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>high mitotic index </strong>is indicative of <strong>aggressive tumor behavior </strong>and <strong>malignancy</strong>, aiding in the <strong>differentiation between benign </strong>and <strong>malignant smooth muscle tumors </strong>such as <strong>leiomyomas </strong>and <strong>leiomyosarcomas</strong>, respectively. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup> 1021</span></strong></span></span></p>",
    "correct_choice_id": 67431,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "DiagnosisBased",
      "Factual"
    ]
  },
  {
    "id": 16873,
    "choices": [
      {
        "id": 67452,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clear cell</span></span></span></p>"
      },
      {
        "id": 67453,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma</span></span></span></p>"
      },
      {
        "id": 67454,
        "text": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Squamous cell carcinoma</span></span></span></p>"
      },
      {
        "id": 67455,
        "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transitional cell carcinoma</span></span></span></p>"
      }
    ],
    "text": "<p style=\"text-align:justify\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common subtype of endometrial carcinoma on histopathology is:</span></span></p>",
    "unique_key": "Q7354322",
    "question_audio": null,
    "question_video": null,
    "map_id": 32332,
    "difficulty_level": "intermediate",
    "subjects_id": [
      5
    ],
    "solution": "<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Adenocarcinoma </span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adenocarcinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the <strong>most common subtype</strong> of <strong>endometrial carcinoma. </strong>The <strong>majority of endometrial cancers </strong>are <strong>adenocarcinomas</strong>, and they are often <strong>classified into two main types</strong>: <strong>endometrioid </strong>and <strong>non-endometrioid</strong>. <strong>Endometrioid adenocarcinoma </strong>is the <strong>most common subtype</strong>, while <strong>clear cell</strong>, <strong>squamous cell</strong>, and <strong>transitional cell carcinomas </strong>are <strong>less common subtypes</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The <strong>majority of endometrial carcinomas </strong>are <strong>adenocarcinomas</strong>, with the <strong>endometrioid type </strong>being the <strong>most prevalent</strong>. It <strong>originates </strong>from the <strong>glandular tissue of the endometrium </strong>and often presents in <strong>postmenopausal women</strong>.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Clear Cell:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Clear cell carcinoma of the <strong>endometrium </strong>is a <strong>rare subtype </strong>and is typically associated with a <strong>more aggressive behavior </strong>and <strong>worse prognosis </strong>than endometrioid adenocarcinoma.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Squamous Cell Carcinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Squamous cell carcinoma of the <strong>endometrium </strong>is <strong>exceedingly rare </strong>because the <strong>endometrium normally </strong>does <strong>not contain squamous cells</strong>; they may appear secondary to metaplastic processes.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Transitional Cell Carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Transitional cell carcinoma is <strong>another rare subtype </strong>of <strong>endometrial cancer </strong>that <strong>resembles urothelial carcinoma of the bladder</strong>. This type of carcinoma is not commonly found in the endometrium.</span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:&nbsp; </span></u></strong></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Adenocarcinoma</strong>, especially the <strong>endometrioid subtype</strong>, is the most <strong>common </strong>form of <strong>endometrial cancer</strong>. </span></span></span></p>\r\n\r\n<p style=\"text-align:justify\">&nbsp;</p>\r\n\r\n<p style=\"text-align:justify\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref</span></u></strong><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Robbins 10<sup>th</sup>/ 1010</span></strong></span></span></p>",
    "correct_choice_id": 67453,
    "solution_audio": null,
    "solution_video": null,
    "audio_explanation_heading": null,
    "video_explanation_heading": null,
    "solution_media_position": "bottom",
    "tags": [
      "ClinicalVignette",
      "TreatmentBased"
    ]
  }
];
        let quizName = 'Male And Female Genital Tract';
        let hierarchy = ["Cerebellum", "qBank", "Pathology"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        const urlParams = new URLSearchParams(window.location.search);
        currentQuestionIndex = Math.min(parseInt(urlParams.get('startAt')) || 0, questionsData.length - 1);

        function goBack() {
            if (isQuizCompleted || confirm('Are you sure you want to leave the quiz? Your progress will be lost.')) {
                window.history.back();
            }
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                setTimeout(processAnswer, 300);
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            setTimeout(showSolution, 1500);
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (!window.location.pathname.endsWith('custom_quiz.html')) {
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>